BMS-986263

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986263 is one of 49 small molecule programs targeting Hepatic fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic FibrosisActive, not recruiting

Liver DiseaseActive, not recruiting

Hepatic FibrosisPhase 2

Active, not recruiting

Liver DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Liver Disease

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 3

—2

Viagra

VViatris Specialty LLC

Phase 3

1 3

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 4

Neurontin

VViatris Specialty LLC

Phase 3

1 5

Sandostatin

Sun Pharma

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Promacta

3 8

Retatrutide

Ozempic

1 10

Jardiance

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Disease1 trial

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04267393·124 enrolled

Hepatic fibrosis1 trial

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03420768·61 enrolled

Impairment1 trial

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04225936·40 enrolled

Tics1 trial

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03142165·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BMS-986263. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986263 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986263. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986263

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Disease1 trial

Hepatic fibrosis1 trial

Impairment1 trial

Tics1 trial

References

Drug Info

Quick Facts

Related News